Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881219 | PMC |
| http://dx.doi.org/10.21037/tau.2017.09.20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preface to "newer techniques and tools lead to a paradigm shift in the diagnosis and management of upper tract urothelial carcinoma".
Transl Androl Urol
September 2024
Department of Urology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
The potential of interleukin-17 inhibitors treatment for reactive arthritis after transurethral resection of a bladder tumor and intravesical administration of bacillus calmette-guerin therapy.
Clin Rheumatol
October 2024
Center for Arthritis and Rheumatic Diseases, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward.
Bladder Cancer
June 2024
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy developed for bladder cancer. This non-replicating recombinant adenovirus vector delivers a copy of the human interferon alpha-2b gene into urothelial and tumor cells, causing them to express this pleotropic cytokine with potent antitumor effects.
Objective: To provide a historical overview describing how several decades of preclinical and clinical studies investigating the role of interferon in the treatment of bladder cancer ultimately led to the development of gene therapy with nadofaragene for NMIBC.
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.
Bladder Cancer
December 2023
Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile.
Article Synopsis
- High-risk non-muscle invasive bladder cancer patients in Latin America have experienced BCG shortages, prompting studies on the effectiveness of reduced-dose (RD) versus full-dose (FD) BCG treatments.
- A retrospective study on 200 patients revealed that those receiving FD BCG had significantly lower recurrence rates and progression to muscle-invasive bladder cancer compared to those on RD BCG.
- Although RD treatment had fewer treatment discontinuations due to toxicity, it was linked to poorer oncological outcomes, suggesting that full-dose BCG is more effective for high-risk patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!